For instance, javanicin was predicted to interact with the human EGFR, a well-known therapeutic target of several drugs, e.g. lapatinib in curing advanced or metastatic breast cancer26, gefitinib and erlotinib for NSCLC therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.